New bispecific monoclonal antibodies under clinical development for patients with RR myeloma
| Bispecific antibody . | Antibody structure . | Target . |
|---|---|---|
| AMG 420 | BiTE | BCMA × CD3 |
| AMG 701 | Extended half-life, scFv plus Fc region | BCMA × CD3 |
| PF-0686135 (elranatamab) | Full-length, humanized IgG2a | BCMA × CD3 |
| REGN5458 | Fc Fab arms | BCMA × CD3 |
| Teclistamab | humanized, IgG Fc | BCMA × CD3 |
| CC-93269 | 2-arm humanized IgG1 Fc, binds bivalently to BCMA and monovalently to CD3 in a 2 + 1 format | BCMA × CD3 |
| TNB-383B | IgG4 Fc. anti-CD3 moiety preferentially activates effector over Tregs; 2 heavy chain-only anti-BCMA moieties | BCMA × CD3 |
| BFCR4350A | Humanized IgG1 Fc | FcRL5 × CD3 |
| Talquetamab | IgG4 Fc | GPRC5D × CD3 |
| Bispecific antibody . | Antibody structure . | Target . |
|---|---|---|
| AMG 420 | BiTE | BCMA × CD3 |
| AMG 701 | Extended half-life, scFv plus Fc region | BCMA × CD3 |
| PF-0686135 (elranatamab) | Full-length, humanized IgG2a | BCMA × CD3 |
| REGN5458 | Fc Fab arms | BCMA × CD3 |
| Teclistamab | humanized, IgG Fc | BCMA × CD3 |
| CC-93269 | 2-arm humanized IgG1 Fc, binds bivalently to BCMA and monovalently to CD3 in a 2 + 1 format | BCMA × CD3 |
| TNB-383B | IgG4 Fc. anti-CD3 moiety preferentially activates effector over Tregs; 2 heavy chain-only anti-BCMA moieties | BCMA × CD3 |
| BFCR4350A | Humanized IgG1 Fc | FcRL5 × CD3 |
| Talquetamab | IgG4 Fc | GPRC5D × CD3 |